stocks logo

ASND

Ascendis Pharma A/S
$
163.320
-0.84(-0.512%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
166.000
Open
164.270
VWAP
--
Vol
337.37K
Mkt Cap
9.86B
Low
160.860
Amount
--
EV/EBITDA(TTM)
--
Total Shares
57.12M
EV
10.33B
EV/OCF(TTM)
--
P/S(TTM)
21.79
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
217.81M
+25.24%
-0.326
-49.04%
176.80M
+205.71%
-0.700
-59.3%
136.23M
+278.43%
-1.391
-27.16%
Estimates Revision
The market is revising Upward the revenue expectations for Ascendis Pharma A/S (ASND) for FY2025, with the revenue forecasts being adjusted by 7.01% over the past three months. During the same period, the stock price has changed by -4.18%.
Revenue Estimates for FY2025
Revise Upward
up Image
+7.01%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+36.17%
In Past 3 Month
Stock Price
Go Down
down Image
-4.18%
In Past 3 Month
15 Analyst Rating
up Image
48.08% Upside
Wall Street analysts forecast ASND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASND is 241.85 USD with a low forecast of 194.00 USD and a high forecast of 400.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
0 Hold
0 Sell
Strong Buy
up Image
48.08% Upside
Current: 163.320
sliders
Low
194.00
Averages
241.85
High
400.00
Citi
Buy
upgrade
$213 -> $243
2025-07-11
Reason
Citi raised the firm's price target on Ascendis Pharma to $243 from $213 and keeps a Buy rating on the shares. The firm updated commercial stage biotechnology targets into the Q2 reports.
Morgan Stanley
Overweight
initiated
$250
2025-07-02
Reason
Morgan Stanley assumed coverage of Ascendis Pharma with an Overweight rating and $250 price target. The firm is positive on the promising commercial trajectory of Yorvipath in hypoparathyroidism and the compelling opportunities presented by the TransCon pipeline, the analyst tells investors in a research note.
Oppenheimer
Oppenheimer
Outperform
maintain
$215 -> $224
2025-06-13
Reason
Oppenheimer raised the firm's price target on Ascendis Pharma to $224 from $215 and keeps an Outperform rating on the shares. The firm's commissioned survey of 20 U.S. hypoparathyroid-treating endocrinologists indicates robust early demand for Yorvipath, with about 20%-30% of its respondents' hypoPT patients expected to be on drug one year hence. While this lines up with the renal impairment rate across the hypoPT population, 90% of its surveyed physicians would reach for Yorvi to preserve kidney function ahead of such impairment. Access/reimbursement was pointed to as the largest adoption hurdle by most of the docs, but this may be more anticipation than reality. Oppenheimer believes Yorvi's strong first full U.S. quarter was just the beginning of a launch that will outpace expectations.
BofA
BofA
Buy
maintain
$201 -> $216
2025-06-09
Reason
BofA raised the firm's price target on Ascendis Pharma to $216 from $201 and keeps a Buy rating on the shares. The firm notes the company announced positive interim 26-week results for the phase 2 COACH trial evaluating combo treatment of QW TransCon CNP + QW TransCon hGH in achondroplasia children. The company guides to COACH 52-week data in Q4 that will be used to optimize the design of a phase 3 combo trial that will initiate in Q4. While BofA notes this is open label data, it views these results favorably as they suggest roughly 3-times better efficacy than TransCon CNP mono. The firm further thinks the update supports a clear differentiated efficacy profile in ACH in addition to weekly dosing that could help Ascendis capture more market share despite likely being 2nd to market. BofA highlights Ascendis as one of its top picks of 2025.
BofA
Tazeen Ahmad
Buy
maintain
$196 -> $201
2025-06-03
Reason
BofA analyst Tazeen Ahmad raised the firm's price target on Ascendis Pharma to $201 from $196 and keeps a Buy rating on the shares after the company announced the NDA submission for TransCon CNP in achondroplasia was accepted by the FDA with a priority review and an assigned PDUFA action date of November 30. The firm, which also notes that the FDA commented that they are not currently planning to hold an advisory committee meeting, thinks the acceptance with priority review and no adcom provides some de-risking of the likelihood of approval and "provides a clear line of sight on a potential timeline to market," the analyst tells investors. The firm increased its view of the U.S. likelihood-of-success for TransCon CNP to 90% from 75% and continues to assume a commercial launch in 2026.
RBC Capital
Luca Issi
Buy
Initiates
$205
2025-04-16
Reason
RBC Capital initiated coverage of Ascendis Pharma (ASND) with an Outperform rating and $205 price target. The stock has outperformed the S&P Biotech ETF XBI lately, but the firm sees more upside from here given that its extensive checks with multiple docs suggest that Yorvipath will be a EUR 3B drug, the analyst tells investors in a research note. Ascendis has a golden opportunity to capitalize on first-mover advantage given that AstraZeneca (AZN) is unlikely differentiated and MBX Biosciences (MBX) is "materially behind", RBC adds.

Valuation Metrics

The current forward P/E ratio for Ascendis Pharma A/S (ASND.O) is -84.24, compared to its 5-year average forward P/E of -19.75. For a more detailed relative valuation and DCF analysis to assess Ascendis Pharma A/S 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-19.75
Current PE
-84.24
Overvalued PE
-5.53
Undervalued PE
-33.96

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-22.70
Current EV/EBITDA
-103.13
Overvalued EV/EBITDA
-4.03
Undervalued EV/EBITDA
-41.37

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
155.20
Current PS
10.94
Overvalued PS
398.83
Undervalued PS
-88.42

Financials

Annual
Quarterly
FY2025Q1
YoY :
+5.28%
100.95M
Total Revenue
FY2025Q1
YoY :
+96.77%
-96.70M
Operating Profit
FY2025Q1
YoY :
-27.79%
-94.63M
Net Income after Tax
FY2025Q1
YoY :
-31.30%
-1.58
EPS - Diluted
FY2025Q1
YoY :
-85.25%
-15.02M
Free Cash Flow
FY2025Q1
YoY :
-10.27%
82.65
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q1
YoY :
-31.41%
-93.73
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 565.41% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.0M
Volume
4
6-9
Months
152.4K
Volume
3
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
4
524.9K
Volume
Months
6-9
5
1.0M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

ASND News & Events

Events Timeline

2025-07-28 (ET)
2025-07-28
07:05:32
Ascendis Pharma announces FDA approved SKYTROFA
select
2025-07-14 (ET)
2025-07-14
16:06:38
Ascendis Pharma announces new data from PaTHway Trial at ENDO 2025
select
2025-06-09 (ET)
2025-06-09
07:07:40
Ascendis Pharma announces interim analysis results from COACH trial
select
Sign Up For More Events

News

9.0
07-28Newsfilter
PinnedFDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency
9.0
07-28NASDAQ.COM
PinnedAscendis Pharma Says FDA Approves SKYTROFA For Adults With Growth Hormone Deficiency
9.0
07-14SeekingAlpha
Ascendis Pharma reports positive results from hypothyroid trial
Sign Up For More News

FAQ

arrow icon

What is Ascendis Pharma A/S (ASND) stock price today?

The current price of ASND is 163.32 USD — it has decreased -0.51 % in the last trading day.

arrow icon

What is Ascendis Pharma A/S (ASND)'s business?

arrow icon

What is the price predicton of ASND Stock?

arrow icon

What is Ascendis Pharma A/S (ASND)'s revenue for the last quarter?

arrow icon

What is Ascendis Pharma A/S (ASND)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Ascendis Pharma A/S (ASND)'s fundamentals?

arrow icon

How many employees does Ascendis Pharma A/S (ASND). have?

arrow icon

What is Ascendis Pharma A/S (ASND) market cap?